1,092 research outputs found
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
AIM: To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronar
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
BACKGROUND: The 2018 US cholesterol management guidelines recommend
additional lipid-lowering therapies for secondary prevention in patients with lowdensity lipoprotein cholesterol â„70 mg/dL or nonâhigh-density lipoprotein cholesterol
â„100 mg/dL despite maximum tolerated statin therapy. Such patients are considered
at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular
disease (ASCVD) event or a single ASCVD event and multiple high-risk conditions.
We investigated the association of US guideline-defined risk categories with the
occurrence of ischemic events after acute coronary syndrome and reduction of
those events by alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9)
inhibitor.
METHODS: In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular
Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab),
patients with recent acute coronary syndrome and residual dyslipidemia despite
optimal statin therapy were randomly assigned to alirocumab or placebo. The primary
trial outcome (major adverse cardiovascular events, ie, coronary heart disease death,
nonfatal myocardial infarction, is
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS
Measurement of the B0-anti-B0-Oscillation Frequency with Inclusive Dilepton Events
The - oscillation frequency has been measured with a sample of
23 million \B\bar B pairs collected with the BABAR detector at the PEP-II
asymmetric B Factory at SLAC. In this sample, we select events in which both B
mesons decay semileptonically and use the charge of the leptons to identify the
flavor of each B meson. A simultaneous fit to the decay time difference
distributions for opposite- and same-sign dilepton events gives ps.Comment: 7 pages, 1 figure, submitted to Physical Review Letter
Measurement of the W+W-gamma Cross Section and Direct Limits on Anomalous Quartic Gauge Boson Couplings at LEP
The process e+e- -> W+W-gamma is analysed using the data collected with the
L3 detector at LEP at a centre-of-mass energy of 188.6GeV, corresponding to an
integrated luminosity of 176.8pb^-1. Based on a sample of 42 selected W+W-
candidates containing an isolated hard photon, the W+W-gamma cross section,
defined within phase-space cuts, is measured to be: sigma_WWgamma = 290 +/- 80
+/- 16 fb, consistent with the Standard Model expectation. Including the
process e+e- -> nu nu gamma gamma, limits are derived on anomalous
contributions to the Standard Model quartic vertices W+W- gamma gamma and W+W-Z
gamma at 95% CL: -0.043 GeV^-2 < a_0/Lambda^2 < 0.043 GeV^-2 0.08 GeV^-2 <
a_c/Lambda^2 < 0.13 GeV^-2 0.41 GeV^-2 < a_n/Lambda^2 < 0.37 GeV^-2
Production of Single W Bosons at \sqrt{s}=189 GeV and Measurement of WWgamma Gauge Couplings
Single W boson production in electron-positron collisions is studied with the
L3 detector at LEP. The data sample collected at a centre-of-mass energy of
\sqrt{s} = 188.7GeV corresponds to an integrated luminosity of 176.4pb^-1.
Events with a single energetic lepton or two acoplanar hadronic jets are
selected. Within phase-space cuts, the total cross-section is measured to be
0.53 +/- 0.12 +/- 0.03 pb, consistent with the Standard Model expectation.
Including our single W boson results obtained at lower \sqrt{s}, the WWgamma
gauge couplings kappa_gamma and lambda_gamma are determined to be kappa_gamma =
0.93 +/- 0.16 +/- 0.09 and lambda_gamma = -0.31 +0.68 -0.19 +/- 0.13
Search for Neutral Higgs Bosons of the Minimal Supersymmetric Standard Model in e+e- Interactions at \sqrt{s} = 189 GeV
A search for the lightest neutral scalar and neutral pseudoscalar Higgs
bosons in the Minimal Supersymmetric Standard Model is performed using 176.4
pb^-1 of integrated luminosity collected by L3 at a center-of-mass energy of
189 GeV. No signal is observed, and the data are consistent with the expected
Standard Model background. Lower limits on the masses of the lightest neutral
scalar and pseudoscalar Higgs bosons are given as a function of tan(beta).
Lower mass limits for tan(beta)>1 are set at the 95% confidence level to be m_h
> 77.1 GeV and m_A > 77.1 GeV
Measurement of Bose-Einstein Correlations in e+e- -> W+W- at root(s)=189GeV
We investigate Bose-Einstein correlations (BEC) in W-pair production at
root(s)=189GeV using the L3 detector at LEP. We observe BEC between particles
from a single W decay in good agreement with those from a light-quark Z decay
sample. We investigate their possible existence between particles coming from
different W's. No evidence for such inter-W BEC is found
Search for an invisibly decaying Higgs boson in e^+e^- collisions at \sqrt{s} = 183 - 189 GeV
A search for a Higgs boson decaying into invisible particles is performed
using the data collected at LEP by the L3 experiment at centre-of-mass energies
of 183 GeV and 189 GeV. The integrated luminosities are respectively 55.3 pb^-1
and 176.4 pb^-1. The observed candidates are consistent with the expectations
from Standard Model processes. In the hypothesis that the production cross
section of this Higgs boson equals the Standard Model one and the branching
ratio into invisible particles is 100%, a lower mass limit of 89.2 GeV is set
at 95% confidence level
Measurement of the Lifetime of the Tau Lepton
The tau lepton lifetime is measured with the L3 detector at LEP using the
complete data taken at centre-of-mass energies around the Z pole resulting in
tau_tau = 293.2 +/- 2.0 (stat) +/- 1.5 (syst) fs. The comparison of this result
with the muon lifetime supports lepton universality of the weak charged current
at the level of six per mille. Assuming lepton universality, the value of the
strong coupling constant, alpha_s is found to be alpha_s(m_tau^2) = 0.319 +/-
0.015(exp.) +/- 0.014 (theory)
- âŠ